Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Critical reviews in oncology/hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CRITREVONC.2004.09.008PMID 15607933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.

  2004cited by this paper
• A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

  2004cited by this paper
• Polynuclear platinum drugs.

  2004cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

  2003cited by this paper
• The cellular pharmacology of oxaliplatin resistance.

  2002cited by this paper
• Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.

  2002cited by this paper
• Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry.

  2001cited by this paper
• Platinum-Based Drugs in Cancer Therapy

  2000cited by this paper
• An update on satraplatin: the first orally available platinum anticancer drug

  2000cited by this paper
• New Platinum Drugs: The Pathway to Oral Therapy

  2000cited by this paper
• Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

  1999cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

  1998cited by this paper
• A protein expression database for the molecular pharmacology of cancer

  1997cited by this paper
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

  1997cited by this paper
• An Information-Intensive Approach to the Molecular Pharmacology of Cancer

  1997cited by this paper
• [Oxaliplatin: the first DACH platinum in clinical practice].

  1997cited by this paper
• The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells.

  1996cited by this paper
• Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry.

  1996cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

  1995cited by this paper
• Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

  1994cited by this paper
• Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS

  1994cited by this paper
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993cited by this paper
• The current status of new platinum analogs.

  1992cited by this paper
• Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

  1990cited by this paper
• Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

  1990cited by this paper
• Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

  1989cited by this paper
• Carboplatin in combination therapy for ovarian cancer.

  1988cited by this paper
• [A cooperative phase II study of cisplatin in patients with head and neck cancer].

  1986cited by this paper
• Chemotherapy of disseminated testicular cancer.

  1985cited by this paper
• High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).

  1980cited by this paper
• [Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].

  1979cited by this paper
• cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.

  1979cited by this paper
• Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.

  1978cited by this paper
• Cis-diamminedichloroplatinum (NSC-119875): a phase I study.

  1973cited by this paper
• Platinum Compounds: a New Class of Potent Antitumour Agents

  1969cited by this paper

• “Non-Classical” Platinum Complexes: A Concise Review

  2025cites this paper
• Antitumor active trans‑platinum complexes through metabolic stability and enhanced cellular accumulation.

  2023cites this paper
• Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

  2022cites this paper
• Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines

  2019cites this paper
• Phytochemicals: Key to Effective Anticancer Drugs

  2019cites this paper
• Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cells

  2018cites this paper
• A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

  2017cites this paper
• A subset of platinum-containing chemotherapeutic agents kill cells by inducing ribosome biogenesis stress rather than by engaging a DNA damage response

  2017cites this paper
• CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF p53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS

  2016influential citation
• Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tum3or cells

  2016cites this paper
• Cytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation.

  2016cites this paper
• A theoretical study on electrons attachment to the trans-[Pt(P)NH3Cl2] (P = 3-picoline or pyridine) and the subsequent interacting with ribose moiety or thymine(T)

  2016cites this paper
• Binding of a potential anti-hepatoma drug cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)-(OCONHC16H33)] with serum albumin – thermodynamic and conformational investigations

  2015cites this paper
• Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.

  2015cites this paper
• Host–guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrins

  2015cites this paper
• Development of Non-Traditional Platinum Anticancer Agents: trans-Platinum Planar Amine Compounds and Polynuclear Platinum Compounds

  2015cites this paper
• Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.

  2015cites this paper
• Pathway-Specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer

  2014cites this paper
• Antitumor activity of semisynthetic derivatives of Aconitum alkaloids

  2014cites this paper
• Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells

  2013cites this paper
• Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand.

  2013cites this paper
• Theoretic study of DNA base guanine and adenine and protein residues’ binding mode of the trans geometries of new antitumor non-classical platinum complexes containing pyridine and picoline ligand

  2013cites this paper
• Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin

  2012cites this paper
• Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data.

  2012cites this paper
• The Challenge of Establishing Reliable Screening Tests for Selecting Anticancer Metal Compounds

  2011cites this paper
• Non-classical structures among current platinum complexes with potential as antitumor drugs.

  2011cites this paper
• Platinum Complexes for the Treatment of Cancer

  2011cites this paper
• Non-classical structures among current platinum complexes with potential as antitumor drugs.

  2011cites this paper
• DNA Reactivity Profile of trans‐Platinum Planar Amine Derivatives

  2011cites this paper
• Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds.

  2011cites this paper
• Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action and Metabolism

  2011influential citation
• Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure–activity relationship modeling

  2010cites this paper
• Theoretical analysis of trans-[PtCl2(NH3)(thiazole)] and trans-[PtCl2(thiazole)2] binding to biological targets — Factors influence binding kinetics and adduct stability

  2010cites this paper
• Core-cross-linked micelles synthesized by clicking bifunctional Pt(IV) anticancer drugs to isocyanates.

  2010cites this paper
• Synthesis and Self-Assembly of Novel Amphiphilic Cisplatin Analogues

  2010cites this paper
• CHARACTERIZATION OF SYNERGISTIC EFFECT OF IODODEOXYURIDINE AND CLOFARABINE IN CISPLATIN-RESISTANT OVARIAN CANCER CELLS By

  2009cites this paper
• Towards Antitumor Active trans-Platinum Compounds.

  2009cites this paper
• DNA bindings of a novel anticancer drug, trans-[PtCl2(isopropylamine)(3-picoline)], and kinetic competition of purine bases with protein residues in the bifunctional substitutions: a theoretical DFT study

  2009cites this paper
• Density Functional Theory Characterization and Descriptive Analysis of Cisplatin and Related Compounds

  2009cites this paper
• Modulation of transplanaramine platinum complex reactivity by systematic modification of carrier and leaving groups

  2009cites this paper
• Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

  2009cites this paper
• Basis for design and development of platinum(IV) anticancer complexes.

  2007cites this paper
• Synthesis and X-ray structure of the dinuclear platinum(II) complex with saccharin {K[Pt(sac)3(H2O)] · H2O}2: Studies on its antiproliferative activity in aqueous solution

  2007cites this paper
• Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes.

  2007influential citation
• Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells

  2006cites this paper
• trans-Platinum planar amine compounds with [N2O2] ligand donor sets: effects of carboxylate leaving groups and steric hindrance on chemical and biological properties.

  2006cites this paper
• Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines

  2006cites this paper
• Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

  2006cites this paper
• The development of platinum compounds and their possible combination.

  2006cites this paper
• Structural and mechanistic aspects of platinum anticancer agents

  2006cites this paper
• Novel transplatinum(II) complexes with [N2O2] donor sets. Cellular pharmacology and apoptosis induction in Pam 212-ras cells.

  2006cites this paper
• Defense System Transporters: Participation in a Chemoimmunity Human Multidrug Resistance ABCB and ABCG

  2006cites this paper
• Donor atom preferences in substitution reactions of trans-platinum mononucleobase compounds : Implications for DNA-protein selectivity

  2006cites this paper
• Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

  2005cites this paper
• Platinum coordination compounds in cancer chemotherapy

  2005cites this paper
• Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

  2005cites this paper
• Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of Antitumor trans-[PtCl2(NH3)(thiazole)]

  2005cites this paper
• New-generation platinum drugs in the treatment of cisplatin-resistant cancers

  2005cites this paper
• Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile.

  2005cites this paper